USNA لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا

03
السعر $14.82
القيمة السوقية (الربع الأخير) $274M
P/E (سنوي حالي) -7.1
ربح السهم (سنوي حالي) $-2.10
الإيرادات (سنوي حالي) $927M
ROE (سنوي حالي) -7.4%
نطاق 52 أسبوعًا $13–$27

USNA مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك

04
نطاق
أشرطة

تتكيف دقة الشريط مع الفترة المحددة - مرر مؤشر الفأرة فوق الرسم البياني لرؤية الافتتاح/الأعلى/الأدنى/الإغلاق للشريط.

تجزئة الأسهم 3
تاريخ الاستحقاق تقسيم النوع
23 نوفمبر، 2016 2-for-1 أمامي
31 أكتوبر، 2003 2-for-1 أمامي
4 أغسطس، 1998 2-for-1 أمامي

حول USANA Health Sciences, Inc. Common Stock نظرة عامة على الشركة من ويكيبيديا

05 · wikidata

USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.

History

In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.

On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.

In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.

USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.

In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.

By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.

The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.

In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.

In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.

Corporate affairs

Leadership

In 2007, USANA faced repeated controversy after members of its board of directors, medical advisory board and several of its executives made false statements regarding their qualifications, including education and licenses.

Founder Myron Wentz was the company's chief executive officer from 1992 until 2008, when his son, Dave Wentz, succeeded him after working in positions such as president, executive vice president, and senior vice president of strategic development. In 2015, USANA announced that the chief executive officer role would be divided between Wentz and Kevin Guest, with the former taking global operations and the latter, field development and sales. Guest was appointed the sole chief executive officer in November 2016.

Operations

USANA, a multilevel marketing company, sells its products primarily through non-employee Brand Partners, as well as through the Internet. The firm's 2010 income disclosure statement defines "associates" as those who are actively building a business, acting as wholesale buyers, or are new distributors. The firm's 2009 SEC 10-K filing distinguishes between associates and preferred customers. Associates are independent distributors of USANA products and also purchase them for personal use. Preferred customers may purchase products at wholesale prices strictly for personal use and are not permitted to resell or distribute them. As of July 2011, the firm had 222,000 active Associates and 68,000 preferred customers. It manufactured 90% of its products at the Salt Lake City headquarters, which produced more than 22 million tablets each week.

Associates may be eligible to receive commissions based on their own product sales as well as through sales made by any new distributors they recruit. According to documentation from USANA corporate, 87 percent of associates fail to make enough from commissions to recover the cost of their qualifying purchases with 67 percent of all associates making no commission; the top 2.31 percent of associates earns 72.2 percent of the company's commissions. According to a 2011 article published by the Salt Lake City Tribune, the firm's FY09 income disclosure statement indicated that the average yearly income of the company's 165,710 associates, which includes those just starting, was $617, while the "top-of-the-pyramid distributors earn an average of $857,865 annually".

USANA sells nutritional, personal care, and food products through Brand Partners and online channels.

USANA classifies Brand Partners and Preferred Customers in its core nutritional business as active customers. There were 387,000 active customers as of January 2026. In 2025, Brand Partners and Preferred Customers each made up about half of all active customers.

Sponsorships

USANA has been a paid sponsor of various athletic organizations. USANA offers an "Athlete Guarantee Program" to select sponsored athletes. The program permits selected participants to enter into an agreement with the company stipulating that, should an athlete enrolled in the program test positive for a banned substance (included in World Anti-Doping Agency regulations) as a result of taking USANA products, the company will compensate the athlete up to two times his or her current annual earnings up to $1 million USD.

In 2006, USANA signed a co-sponsorship agreement with the WTA Tour and extended it in 2011. The agreement provides athletes with nutritional supplements that are guaranteed to conform to the Tour's antidoping policy. As part of the agreement in 2011, USANA donated $1 to Children's Hunger Fund for every ace scored at a WTA tournament beginning at Wimbledon and continuing through the end of the season. USANA provided its products to 40 athletes at the Turin Olympics and worked with various sports organizations, including the Professional Rodeo Cowboys Association.

In 2003, USANA became the title sponsor of the USANA Amphitheatre, an outdoor amphitheatre based in West Valley City, Utah with a seating capacity of 20,000. In May 2012, United Concerts announced a continued naming rights partnership with USANA Health Sciences through March 2018.

In 2020, USANA became the title partner of U.S. Ski & Snowboard's training and education facility, the Center of Excellence. The facility is a training hub used by Olympians, youth athletes, and various international competitions.

In the lead-up to the 2020 Summer Olympics, USANA announced partnerships with USA Swimming and the USA Skateboarding National Team. It was the official multivitamin sponsor of USA Swimming and official nutritional supplement supplier of USA Skateboarding. The partnerships reportedly extended into multi-year agreements.

Products

USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).

USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.

USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.

Reception

From 2004 to 2006, USANA was named on Forbes "200 Best Small Companies" list. In 2007, a Forbes article quoted industry experts and government officials who had raised questions about the cost of USANA's supplements and its business practices. Radio-Canada later aired an investigative report that examined the company's products, pricing and "misleading income claims" made to potential associates concerning revenue. It included hidden-camera footage of recruitment and other sessions, which found one group of associates appeared to violate the company's policies and distributor agreements. This contrasted with the Canadian legal requirements for multi-level marketing companies to provide clear, frequent and complete information about the revenue of the typical participant. In addition, the same group of associates were filmed making recommendations for using USANA products to treat illnesses including leukemia.

John Cloud, senior writer for Time Magazine, evaluated nutritional supplements in which he took a regimen of USANA pills, protein bars, powder drinks and psyllium fiber as recommended by the company's online evaluation. Cloud took a blood test before starting the products to measure levels of calcium, protein, sodium, cholesterol, glucose, and other substances, and was then tested again five months after starting the supplement regimen, which included 3,000 pills at a cost of $1,200. The follow-up test revealed a change in only two values; a 75% increase in vitamin D levels (attributed to the vitamin D3 supplement Cloud had been taking) and a 28 mg/dl increase in high-density lipoprotein, which could not be accounted for. Cloud also experienced a placebo response where that act of taking the supplements made him feel more vigorous despite no physiological reasons being present. This response also led to a 10-lb weight gain, as the belief that he was more vigorous led him to make poorer dietary decisions—a phenomenon referred to as the "licensing effect".

New Zealand government statistician for the Commerce Commission, Murray H. Smith, who served as an expert witness in every pyramid scheme case brought by the Commission preceding 10 years, opined in 2008 that very few USANA distributors are likely to become wealthy, and stated, "you can make a very strong argument that this could be a pyramid scheme." When asked by the National Business Review to review the firm's business structure and compensation plan, it was Smith's opinion, from a statistical not legal standpoint, that the firm demonstrated a number of characteristics commonly occurring in pyramid schemes including that most members recoup less than what they pay to participate; that those at the top of the structure are more likely to make more than those on the bottom of the structure; and that as the company grows it will become harder to recruit others. Smith also noted the company's significant turnover in distributors making it necessary to continually recruit.

المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗

Wikidata ↗

قطاعConsumer products صناعةConsumer products موظفون1570 بلدUS

أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم

06
الإيرادات$925M
2016-12-31 → 2026-01-03
ربح السهم$0.58
2016-12-31 → 2026-01-03
التدفق النقدي الحر$9M
2016-12-31 → 2026-01-03
هامش صافي-4.2%
2016-12-31 → 2026-01-03
التقييم والنسب 07–12

التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟

المقياس اتجاه 5 سنوات USNA متوسط 5 سنوات متوسط الأقران الحكم
P/E (سنوي حالي) -7.1متوسط 5 سنوات ≈19.7 ≈19.7 · ·
السعر/المبيعات (سنوي حالي) 0.3متوسط 5 سنوات ≈1.0 ≈1.0 1.2 مقوّم بأقل من قيمته
السعر / القيمة الدفترية (الربع الأخير) 0.5متوسط 5 سنوات ≈2.3 ≈2.3 2.4 مقوّم بأقل من قيمته
السعر / التدفق النقدي الحر (سنوي حالي) -16.8متوسط 5 سنوات ≈20.5 ≈20.5 · ·
السعر / التدفق النقدي (سنوي حالي) -157.2متوسط 5 سنوات ≈13.5 ≈13.5 16.8 القيمة العادلة
السعر / القيمة الدفترية الملموسة (الربع الأخير) 0.7متوسط 5 سنوات ≈3.0 ≈3.0 · ·

يتم حساب الوسيط النظير على أساس موحد لكل مقياس وقد لا يتطابق دائمًا مع الأساس السنوي الحالي/الربع الأخير المعروض لهذا السهم.

القيمة · ≈ متوسط 5 سنوات · متوسط الصناعة · حكم مقارنة بالمتوسط

سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي

14
متوسط المفاجأة -21.9%
التقرير القادم أكتوبر 19, 2026
الفترةتقريرEPS ActualEPS المتوقعالمفاجأة
30 يونيو، 2026 يوليو 20, 2026 $-0.07 $0.44 -116.0%
31 مارس، 2026 $0.61 $0.45 35.9%
31 ديسمبر، 2025 $0.60 $0.42 43.5%
30 سبتمبر، 2025 $-0.15 $0.48 -131.3%
30 يونيو، 2025 $0.74 $0.55 34.4%
31 مارس، 2025 $0.73 $0.71 2.2%

الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي

15
قائمة الدخل 18
المقياس اتجاه 202520242023202220212020201920182017201620152014
Revenue $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Cost of Revenue $201M$161M$177M$194M$218M$209M$188M$201M$179M$180M$160M$141M
Gross Profit $724M$693M$744M$805M$969M$926M$873M$989M$868M$826M$759M$650M
R&D Expense $11M$12M$11M$12M$11M$11M$10M$10M$9M$9M$6M$5M
SG&A Expense $337M$263M$257M$262M$279M$261M$268M$275M$265M$234M$209M$185M
Operating Expenses $687M$627M$651M$697M$798M$749M$727M$800M$735M$687M$617M$534M
Operating Income $37M$66M$93M$108M$170M$176M$146M$188M$133M$139M$142M$116M
Interest Expense ··$262.0K$192.0K$57.0K$507.0K$66.0K$36.0K$46.0K$444.0K$15.0K$129.0K
Interest Income $2M$11M$10M$4M$3M$3M$5M$4M$2M$1M$1M$500.0K
Other Non-op $3M$-1M$7.0K$-3M$-2M$-571.0K$-335.0K$-1M$-3.0K$-1M$-174.0K$-820.0K
Pretax Income $42M$76M$102M$109M$171M$178M$150M$192M$135M$139M$143M$116M
Income Tax $30M$34M$39M$39M$54M$53M$50M$65M$72M$39M$48M$39M
Net Income $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
EPS (Basic) $0.58$2.20$3.31$3.60$5.78$5.89$4.44$5.24$2.57$4.14$3.72$2.90
EPS (Diluted) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Shares (Basic) 18,535,00019,103,00019,250,00019,254,00020,146,00021,156,00022,644,00024,105,00024,349,00024,185,00025,460,00026,443,000
Shares (Diluted) 18,574,00019,162,00019,345,00019,310,00020,343,00021,256,00022,818,00024,642,00024,708,00025,047,00026,355,00027,377,000
EBITDA $70M$81M$106M$121M$183M$190M$161M$205M$149M$152M$152M$125M
الميزانية العمومية 26
المقياس اتجاه 202520242023202220212020201920182017201620152014
Cash & Equivalents $158M$182M$330M$288M$240M$312M$235M$214M$247M$176M$143M$111M
Receivables $4M···········
Inventory $103M$70M$61M$67M$98M$90M$69M$82M$63M$65M$66M$45M
Prepaid Expense $23M$28M$26M$29M$27M$23M$26M$33M$30M$37M$35M$35M
Other Current Assets $5M$5M$6M$7M$4M$5M$5M$7M$5M$6M$5M$6M
Current Assets $288M$279M$418M$384M$365M$425M$329M$392M$340M$278M$244M$191M
PP&E (Net) $94M$95M$100M$98M$102M$100M$95M$92M$103M$101M$88M$71M
PP&E (Gross) ··$212M$210M$211M$199M$181M$178M$177M$164M$120M$114M
Accum. Depreciation $135M$130M$129M$125M$122M$116M$105M$96M$86M$76M$71M$64M
Goodwill $138M$144M$17M$17M$18M$17M$17M$17M$17M$17M$17M$18M
Intangibles $133M$152M$30M$32M$30M$31M$30M$32M$35M$34M$38M$41M
Other Non-current Assets $62M$59M$55M$55M$58M$62M$43M$18M$21M$22M$25M$24M
Total Assets $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Accounts Payable $17M$12M$10M$11M$14M$18M$13M$10M$12M$9M$10M$8M
Accrued Liabilities $10M$14M$10M·········
Current Liabilities $129M$140M$119M$144M$161M$168M$136M$149M$141M$138M$131M$109M
Capital Leases $12M$10M$5M$8M$10M·$17M·····
Deferred Tax $5M$4M$5M$4M$7M$12M$10M$13M$14M$5M$10M$11M
Other Non-current Liabilities $23M$18M$12M$14M$14M$19M$19M$1M$1M$1M$1M$1M
Total Liabilities $157M$162M$136M·········
Common Stock $18.0K$19.0K$19.0K$19.0K$19.0K$21.0K$22.0K$24.0K$24.0K$24.0K$25.0K$13.0K
Retained Earnings $466M$479M$445M$392M$345M$383M$306M$330M$288M$265M$215M$166M
AOCI $-16M$-23M$-14M$-13M$458.0K$-4M$-14M$-10M$-1M$-12M$-4M$2M
Stockholders' Equity $533M$532M$497M$434M$395M$442M$352M$391M$363M$325M$281M$230M
Liabilities + Equity $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Shares Outstanding 18,281,00019,064,00019,130,00019,206,00019,393,00021,038,00021,655,00023,567,00024,024,00024,485,00024,976,00025,266,000
التدفق النقدي 16
المقياس اتجاه 202520242023202220212020201920182017201620152014
D&A $33M$15M$13M$13M$13M$14M$15M$17M$16M$13M$10M$9M
Stock-based Comp $14M$15M$15M$13M$14M$14M$16M$15M$15M$17M$11M$10M
Deferred Tax $-7M$-7M$-3M$-7M$-3M$-2M$-4M$607.0K$19M$-4M$-3M$-1M
Amort. of Intangibles $19M$2M$2M$2M$1M$1M$1M$2M$1M$2M$900.0K$431.0K
Restructuring $6M$0$0·········
Other Non-cash $-28M$-3M$-18M$15M$-20M$10M$-442.0K$-7M$10M$11M$-2M$11M
Operating Cash Flow $22M$61M$71M$104M$121M$160M$127M$152M$124M$137M$111M$105M
CapEx $14M$10M$14M$10M$13M$15M$17M$11M$13M$33M$24M$20M
Investing Cash Flow $-10M$-213M$-12M$-12M$-14M$-34M$47M$-69M$-13M$-32M$-25M$-16M
Stock Repurchased $28M$9M$12M$25M$178M$57M$150M$105M$50M$65M$61M$139M
Net Stock Activity $-28M$-9M$-12M$-25M$-178M$-57M$-150M$-105M$-50M$-65M$-61M$-139M
Financing Cash Flow $-41M$10M$-14M$-30M$-181M$-59M$-152M$-105M$-50M$-65M$-49M$-113M
Net Change in Cash $-23M$-149M$42M$48M$-72M$78M$20M$-33M$72M$32M$32M$-26M
Taxes Paid $37M$40M$42M·········
Free Cash Flow $9M$51M$56M$94M$108M$145M$110M$141M$111M$104M$88M$85M
Levered FCF ··$56M$93M$108M$145M$110M$141M$111M$104M$88M$85M
الربحية 8
المقياس اتجاه 202520242023202220212020201920182017201620152014
Gross Margin 78.3%81.1%80.8%80.6%81.6%81.6%82.3%83.1%82.9%82.1%82.6%82.2%
Operating Margin 4.0%7.8%10.1%10.8%14.3%15.6%13.8%15.8%12.7%13.8%15.4%14.7%
Net Margin 1.2%4.9%6.9%6.9%9.8%11.0%9.5%10.6%6.0%9.9%10.3%9.7%
Pretax Margin 4.5%8.9%11.1%10.9%14.4%15.7%14.2%16.1%12.9%13.8%15.5%14.6%
EBITDA Margin 7.6%9.5%11.5%12.1%15.4%16.8%15.2%17.2%14.2%15.1%16.5%15.8%
ROA 1.4%6.1%10.4%11.8%19.1%21.5%18.8%23.5%12.6%22.4%24.5%21.3%
ROE 2.0%7.9%13.2%16.4%29.3%30.0%30.2%30.5%17.2%33.0%37.0%31.2%
ROIC 1.9%6.9%11.7%15.8%29.4%28.0%27.8%31.7%16.9%30.8%33.5%33.4%
السيولة والملاءة 3
المقياس اتجاه 202520242023202220212020201920182017201620152014
Current Ratio 2.22.03.52.72.32.52.42.62.42.01.91.8
Quick Ratio 1.21.32.82.01.51.91.71.41.81.31.11.0
Interest Coverage ··355.2560.52985.8348.12215.05232.02880.5312.29444.1900.0
الكفاءة 2
المقياس اتجاه 202520242023202220212020201920182017201620152014
Asset Turnover 1.21.21.51.71.92.02.02.22.12.32.42.2
Inventory Turnover 2.32.52.72.32.32.22.52.82.82.82.93.0
لكل سهم 5
المقياس اتجاه 202520242023202220212020201920182017201620152014
Book Value / Share $29.16$27.91$25.99$22.62$20.37$20.99$16.24$16.60$15.12$13.29$22.49$18.22
Revenue / Share $49.81$44.59$47.61$51.71$58.32$53.38$46.49$48.26$42.39$40.17$69.70$57.74
Cash Flow / Share $1.20$3.18$3.65$5.38$5.96$7.55$5.55$6.17$5.01$5.47$8.46$7.68
Cash / Share $8.66$9.53$17.27$15.02$12.37$14.83$10.84$9.09$10.29$7.18$11.47$8.80
EPS (TTM) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
معدلات النمو 9
المقياس اتجاه 202520242023202220212020201920182017201620152014
Revenue YoY 8.3%-7.2%-7.8%-15.8%4.6%·······
Revenue CAGR 3Y -2.5%-10.4%-6.7%·········
Revenue CAGR 5Y -4.0%···········
EPS YoY -73.5%-33.6%-8.1%-37.4%-2.2%·······
EPS CAGR 3Y -45.5%-27.4%-17.4%·········
EPS CAGR 5Y -37.0%···········
Net Income YoY -74.4%-34.1%-8.0%-40.5%-6.5%·······
Net Income CAGR 3Y -46.3%-28.8%-20.0%·········
Net Income CAGR 5Y -38.7%···········
التقييم (آخر 12 شهرًا) 10
المقياس اتجاه 202520242023202220212020201920182017201620152014
Revenue TTM $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Net Income TTM $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
Market Cap $355M$680M$1.03B$1.02B$1.96B$1.62B$1.73B$2.71B$1.78B$1.50B$798M$646M
P/E 33.516.316.214.817.713.218.122.529.315.317.818.3
P/S 0.40.81.11.01.71.41.62.31.71.50.90.8
P/B 0.71.32.12.45.03.74.96.94.94.62.82.8
P / Tangible Book 1.42.92.32.75.74.1······
P / Cash Flow 15.911.214.59.816.210.113.717.814.410.97.26.1
P / FCF 41.713.418.310.918.111.215.719.316.114.49.17.6
Earnings Yield 3.0%6.1%6.2%6.8%5.7%7.6%5.5%4.5%3.4%6.5%5.6%5.5%

أحدث فترة على اليسار · القيم الفارغة معروضة كـ ·

القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات

16
المقياس 2026-01-032024-12-282023-12-302022-12-312022-01-01
الإيرادات $925M $855M $921M $999M $1.19B
هامش الربح الإجمالي % 78.3% 81.1% 80.8% 80.6% 81.6%
هامش الربح التشغيلي % 4.0% 7.8% 10.1% 10.8% 14.3%
صافي الدخل $11M $42M $64M $69M $117M
EPS المخفف $0.58 $2.19 $3.30 $3.59 $5.73

الملاك المؤسسيون (13F) 151 مقدمي إقرار · $260.7M إجمالي · حتى تاريخ 30 سبتمبر، 2026

17

المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.

حائزون 151
القيمة المحتفظ بها $260.7M
مراكز جديدة 25
المراكز الخارجة 17
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
مراكز جديدة المراكز الخارجة زيادة انخفض صافي التغير في الأسهم
25 (-5 مقابل الربع السابق) 17 (+8 مقابل الربع السابق) 60 (+21 مقابل الربع السابق) 30 (-19 مقابل الربع السابق) +1.2M

مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.

مؤسسة القيمة الأسهم % من 13F المتتبعة النوع
BlackRock, Inc. $33181935 1554189 12,73% الأسهم
PZENA INVESTMENT MANAGEMENT LLC $25739282 1205587 9,87% الأسهم
RENAISSANCE TECHNOLOGIES LLC $20464402 958520 7,85% الأسهم
VANGUARD GROUP INC $18340623 934316 7,03% الأسهم
DIMENSIONAL FUND ADVISORS LP $17878705 837426 6,86% الأسهم
Nantahala Capital Management, LLC $17295080 810074 6,63% الأسهم
VANGUARD CAPITAL MANAGEMENT LLC $10405350 487370 3,99% الأسهم
Creative Planning $8923681 417971 3,42% الأسهم
AQR CAPITAL MANAGEMENT LLC $8712637 408086 3,34% الأسهم
VANGUARD PORTFOLIO MANAGEMENT LLC $7758099 363377 2,98% الأسهم
GEODE CAPITAL MANAGEMENT, LLC $6047019 283165 2,32% الأسهم
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $5811641 272208 2,23% الأسهم
STATE STREET CORP $5577474 261240 2,14% الأسهم
Nuveen, LLC $5112835 239477 1,96% الأسهم
AMERICAN CENTURY COMPANIES INC $3999880 187348 1,53% الأسهم
JACOBS LEVY EQUITY MANAGEMENT, INC $3855105 180567 1,48% الأسهم
TWO SIGMA INVESTMENTS, LP $3533724 165514 1,36% الأسهم
MORGAN STANLEY $3509150 164363 1,35% الأسهم
D. E. Shaw & Co., Inc. $3348427 156835 1,28% الأسهم
Allianz Asset Management GmbH $3040219 142399 1,17% الأسهم
BRIDGEWAY CAPITAL MANAGEMENT, LLC $2949567 138153 1,13% الأسهم
ALGERT GLOBAL LLC $2813033 131758 1,08% الأسهم
GOLDMAN SACHS GROUP INC $2631750 123267 1,01% الأسهم
UBS Group AG $2474166 115886 0,95% الأسهم
LAZARD ASSET MANAGEMENT LLC $2077590 97311 0,80% الأسهم
NORTHERN TRUST CORP $2016870 94467 0,77% الأسهم
AMERIPRISE FINANCIAL INC $1552893 72735 0,60% الأسهم
VANGUARD FIDUCIARY TRUST CO $1549540 72578 0,59% الأسهم
Vanguard Global Advisers, LLC $1514569 70940 0,58% الأسهم
Empowered Funds, LLC $1499902 70253 0,58% الأسهم
TWO SIGMA ADVISERS, LP $1289691 65700 0,49% الأسهم
Bank of New York Mellon Corp $1104521 51734 0,42% الأسهم
Quantinno Capital Management LP $1072261 50223 0,41% الأسهم
BANK OF AMERICA CORP /DE/ $967539 45318 0,37% الأسهم
ROYCE & ASSOCIATES LP $884039 41407 0,34% الأسهم
DEUTSCHE BANK AG\ $821975 38500 0,32% الأسهم
Assenagon Asset Management S.A. $815848 38213 0,31% الأسهم
BARCLAYS PLC $777141 36400 0,30% الأسهم
STRS OHIO $723765 33900 0,28% الأسهم
Skopos Labs, Inc. $673696 38563 0,26% الأسهم
HSBC HOLDINGS PLC $672758 31960 0,26% الأسهم
Invesco Ltd. $670775 31418 0,26% الأسهم
SEI INVESTMENTS CO $641513 30047 0,25% الأسهم
XTX Topco Ltd $625320 29289 0,24% الأسهم
CITADEL ADVISORS LLC $575617 26961 0,22% الأسهم
MILLENNIUM MANAGEMENT LLC $570728 26732 0,22% الأسهم
Verdad Advisers, LP $556552 26068 0,21% الأسهم
Inspire Investing, LLC $512954 29362 0,20% الأسهم
Sanctuary Advisors, LLC $497113 23284 0,19% الأسهم
Man Group plc $489854 22944 0,19% الأسهم

عرض جميع الملاك المؤسسيين البالغ عددهم 151 →

الناشطون والمالكون بنسبة 5%+ 3 حيازات

18

المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.

مقدم مقدم حصة الحالة الغرض إيداع
Gull Global Limited, Myron W. Wentz ×11 إيداعات 30 مارس، 2026 40,10% تعديل اندماج واستحواذ / بيع SEC
Gull Holdings, Ltd., Myron W. Wentz, David A. Wentz, Jacquelyn R. Wentz, Bryan Wentz, Annette Wentz, Paul & Jane Meyer Family Foundation, Paul James Meyer, Alice Jane Meyer, Centre Island Properties, Ltd., Waco Boys Club Foundation, Inc., L-K Marketing Group, LLC, Beagle Irrevocable Asset Trust 23 مايو، 2008 · إيداع أولي · SEC
Paul & Jane Meyer Family Foundation 20 مايو، 2008 · إيداع أولي استثمار سلبي SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

المطلعون على الشركة 38 من المطلعين · مسؤولون 20 · مديرون 13

19
مطلع الدور آخر نشاط الأسهم المملوكة مشتريات 12 شهرًا مبيعات 12 شهرًا صافي 12 شهرًا
Jim Brown CEO & PRESIDENT 24 يوليو، 2025 M 16934 0 0 $0
Doug G Iiekking CHIEF FINANCIAL OFFICER 27 مايو، 2026 S 0 0 1 $-100500
Jeffrey Yates Chief Financial Officer 28 أكتوبر، 2010 M 0 0 0 $0
Deborah Woo President of Asia 8 سبتمبر، 2016 M 1479 0 0 $0
Fred W Cooper President and COO 28 أكتوبر، 2010 M 0 0 0 $0
Walter Noot CHIEF OPERATING OFFICER 27 فبراير، 2026 M 9256 0 0 $0
Roy Truett Chief Operating Officer 27 يوليو، 2012 M 0 0 0 $0
Kathryn Michelle Armstrong CHIEF SCIENTIFIC OFFICER 25 يوليو، 2026 M 3471 0 0 $0
Peter Benedict CHIEF INFORMATION OFFICER 25 يوليو، 2026 M 422 0 2 $-144236
Brent Neidig CHIEF COMMERCIAL OFFICER 16 يونيو، 2026 S 0 0 3 $-147749
Paul A. Jones CHIEF PEOPLE OFFICER 8 يونيو، 2026 S 0 0 2 $-231984
Joshua Foukas CHIEF LEGAL OFFICER 7 مايو، 2026 S 0 0 2 $-170336
David Mulham Mulham CHIEF SALES OFFICER 10 ديسمبر، 2025 S 8387 0 1 $-18333
Daniel A. Macuga CHIEF COMMUNICATIONS OFFICER 2 مايو، 2024 S 0 0 0 $0
Robert A Sinnott CHIEF SCIENTIFIC OFFICER 5 مارس، 2024 S 0 0 0 $0
James Bramble Chief Legal Officer and Sec 5 فبراير، 2018 A 2076 0 0 $0
Dave Wentz Co-C.E.O. 16 أغسطس، 2016 M 384883 0 0 $0
Rick Stambaugh Chief Information Officer 17 ديسمبر، 2015 M 0 0 0 $0
Mark H Wilson E.V.P. of Sales 28 أكتوبر، 2010 M 5000 0 0 $0
Bradford Richardson E.V.P. of Asia Pacific 25 فبراير، 2008 S 0 0 0 $0
Xia Ding مدير 23 يوليو، 2026 M 8278 0 0 $0
John Turman Fleming مدير 23 يوليو، 2026 M 5862 0 2 $-78560
Peggie Pelosi مدير 23 يوليو، 2026 M 6061 0 0 $0
Scott J Nixon مدير 23 يوليو، 2026 M 11445 0 0 $0
Frederic J Winssinger مدير 23 يوليو، 2026 M 9733 0 1 $-38420
Timothy E Wood مدير 23 يوليو، 2026 M 11837 0 0 $0
Gilbert A Fuller مدير 23 يوليو، 2026 M 1632 0 3 $-60414
Robert Auciaux مدير 9 مايو، 2022 M 8092 0 0 $0
Feng Peng مدير 28 إبريل، 2021 M 755 0 0 $0
Myron W. Wentz مدير 4 فبراير، 2019 S 9865614 0 0 $0
Jerry G Mcclain مدير 4 مارس، 2016 M 0 0 0 $0
Ronald S Poelman مدير 8 فبراير، 2016 A 0 0 0 $0
Denis E Waitley مدير 3 نوفمبر، 2006 M 0 0 0 $0
Gull Global Limited مالك 10% 4 فبراير، 2019 S 9865614 0 0 $0
GULL HOLDINGS LTD مالك 10% 1 إبريل، 2015 J 6491110 0 0 $0
Kevin Guest · 27 فبراير، 2026 M 45381 0 0 $0
Donald R. Williams · 1 مايو، 2017 A · 0 0 $0
Doug Braun · 16 ديسمبر، 2015 M 0 0 0 $0

المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط

ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 22 صناديق مؤشرات متداولة

20

الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.

صندوق الوزن الوحدات حتى تاريخ المصدر
VFVA · VANGUARD WELLINGTON FUND 0,11% 45046 SH 19 أغسطس، 2026 يومي
EBIT · Harbor ETF Trust 0,07% 367 NS 31 يوليو، 2026 N-PORT
IWC · iShares Trust 0,04% 37870 SH 11 سبتمبر، 2026 يومي
VDC · VANGUARD WORLD FUND 0,03% 128565 SH 19 أغسطس، 2026 يومي
VTWV · VANGUARD SCOTTSDALE FUNDS 0,02% 9639 SH 19 أغسطس، 2026 يومي
DFSV · Dimensional ETF Trust 0,02% 67386 NS 31 يوليو، 2026 N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust 0,01% 23709 SH 2 أكتوبر، 2026 يومي
DFAT · Dimensional ETF Trust 0,01% 67428 NS 31 يوليو، 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,01% 64278 SH 19 أغسطس، 2026 يومي
RSSL · Global X Funds 0,01% 5337 NS 31 يوليو، 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,01% 1189 SH 1 أكتوبر، 2026 يومي
DFAS · Dimensional ETF Trust 0,01% 42099 NS 31 يوليو، 2026 N-PORT
IWM · iShares Trust 0,01% 283783 SH 11 سبتمبر، 2026 يومي
DFAC · Dimensional ETF Trust 0,00% 19278 NS 31 يوليو، 2026 N-PORT
ITOT · iShares Trust 0,00% 22756 SH 11 سبتمبر، 2026 يومي
IWV · iShares Trust 0,00% 3720 SH 3 سبتمبر، 2026 يومي
DFUS · Dimensional ETF Trust 0,00% 1784 NS 31 يوليو، 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,00% 124681 SH 19 أغسطس، 2026 يومي
VTI · VANGUARD INDEX FUNDS 0,00% 350035 SH 19 أغسطس، 2026 يومي
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 790 SH 19 أغسطس، 2026 يومي
IWN · iShares Trust · 101470 SH 11 سبتمبر، 2026 يومي
SMLF · iShares Trust · 22964 SH 11 سبتمبر، 2026 يومي

USNA توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود

21
تصنيف · 6 محللين بيع
السعر المستهدف الوسيط $25.00 +68,7%
0 0,0% شراء قوي
0 0,0% شراء
3 50,0% احتفاظ
1 16,7% بيع
2 33,3% بيع قوي

السعر المستهدف لمدة 12 شهرًا

1 محللين · 2026-10-01

السعر المستهدف المتوسط $25.00 +68,7%

منخفض$25.00 المتوسط$25.00 مرتفع$25.00

مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع

22

أساس السنة المالية، الأسعار كما في إغلاق نهاية السنة المالية الأخيرة لكل شركة.

الرمز القيمة السوقية P/E الإيرادات سنويًا هامش الربح الصافي ROE هامش الربح الإجمالي
USNA $355M 33.5 8.3% 1.2% 2.0% 78.3%
EPC $946M 38.4 -1.3% 1.1% 1.7% 41.6%
BRBR $4.39B 21.6 16.1% 9.3% -72.0% 33.3%
HNST $291M -18.4 -1.9% -4.2% -8.8% 33.3%
NUS · 3.0 -14.3% 10.8% 22.0% 69.5%
NAGE $507M 31.8 29.9% 13.4% 24.7% 64.3%
NATR $378M 20.4 5.7% 4.1% 12.0% 72.4%
MED $117M -6.3 -36.0% -4.8% -9.0% 71.3%

مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة

26

اختر المقاييس التي تهمك — انقر فوق علامة + بجوار أي صف في الأساسيات الكاملة أعلاه.

يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.

المصدر: إيداع SEC 10-Q بتاريخ أغسطس 13, 2026